IL49126A0 - Quinolone derivatives - Google Patents

Quinolone derivatives

Info

Publication number
IL49126A0
IL49126A0 IL49126A IL4912676A IL49126A0 IL 49126 A0 IL49126 A0 IL 49126A0 IL 49126 A IL49126 A IL 49126A IL 4912676 A IL4912676 A IL 4912676A IL 49126 A0 IL49126 A0 IL 49126A0
Authority
IL
Israel
Prior art keywords
quinolone derivatives
quinolone
derivatives
Prior art date
Application number
IL49126A
Other languages
English (en)
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB11644/75A external-priority patent/GB1502312A/en
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of IL49126A0 publication Critical patent/IL49126A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL49126A 1975-03-20 1976-03-01 Quinolone derivatives IL49126A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB11644/75A GB1502312A (en) 1975-03-20 1975-03-20 Quinolone derivatives
GB4204375 1975-10-14

Publications (1)

Publication Number Publication Date
IL49126A0 true IL49126A0 (en) 1976-05-31

Family

ID=26248416

Family Applications (1)

Application Number Title Priority Date Filing Date
IL49126A IL49126A0 (en) 1975-03-20 1976-03-01 Quinolone derivatives

Country Status (19)

Country Link
US (1) US4066651A (instruction)
JP (1) JPS51118773A (instruction)
AU (1) AU1147676A (instruction)
CS (1) CS188273B2 (instruction)
DD (1) DD124117A5 (instruction)
DE (1) DE2611824A1 (instruction)
DK (1) DK115376A (instruction)
ES (1) ES446234A1 (instruction)
FI (1) FI760729A7 (instruction)
FR (1) FR2304342A1 (instruction)
HU (1) HU172032B (instruction)
IE (1) IE43079B1 (instruction)
IL (1) IL49126A0 (instruction)
LU (1) LU74594A1 (instruction)
NL (1) NL7602834A (instruction)
NO (1) NO760993L (instruction)
PT (1) PT64921B (instruction)
SE (1) SE434394B (instruction)
SU (1) SU648090A3 (instruction)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK0382185T3 (da) * 1989-02-10 1994-07-04 Otsuka Pharma Co Ltd Carbostyrilderivater
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
AU8665991A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds and antihypertensive compounds
TW198715B (instruction) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
EP0543018B1 (en) * 1991-06-07 1996-01-10 Otsuka Pharmaceutical Co., Ltd. Antidiabetic agent
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
KR20020038741A (ko) 1999-08-27 2002-05-23 윌리암 엘. 레스페스 안드로겐 수용체 조절 화합물 및 방법
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
JP2003529545A (ja) 1999-09-14 2003-10-07 リガンド・ファーマシューティカルズ・インコーポレイテッド 改善された薬理学的プロファイルを有するrxrモジュレーター
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
AU2004266160A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN103342695B (zh) 2007-09-14 2015-04-22 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
EA016969B1 (ru) * 2007-09-14 2012-08-30 Аддекс Фарма С.А. 1,3-двузамещенные-4-фенил-1н-пиридин-2-оны
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온
WO2009062676A2 (en) * 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2705376A1 (en) * 2007-11-15 2009-05-22 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760741C (en) 2009-05-12 2018-05-01 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772301A (en) * 1971-11-22 1973-11-13 Warner Lambert Co (4-substituted)4-(methylsulfinyl)methylcarbostyrils

Also Published As

Publication number Publication date
LU74594A1 (instruction) 1977-05-06
NL7602834A (nl) 1976-09-22
CS188273B2 (en) 1979-02-28
IE43079L (en) 1976-09-20
JPH0122267B2 (instruction) 1989-04-25
NO760993L (instruction) 1976-09-21
JPS51118773A (en) 1976-10-18
FI760729A7 (instruction) 1976-09-21
DE2611824A1 (de) 1976-09-30
SU648090A3 (ru) 1979-02-15
SE434394B (sv) 1984-07-23
PT64921B (en) 1977-08-24
DD124117A5 (instruction) 1977-02-02
ES446234A1 (es) 1977-10-01
PT64921A (en) 1976-04-01
HU172032B (hu) 1978-05-28
FR2304342A1 (fr) 1976-10-15
US4066651A (en) 1978-01-03
AU1147676A (en) 1977-09-01
DE2611824C2 (instruction) 1987-06-19
DK115376A (da) 1976-09-21
FR2304342B1 (instruction) 1979-09-21
IE43079B1 (en) 1980-12-17
SE7602339L (sv) 1976-09-21

Similar Documents

Publication Publication Date Title
IL49126A0 (en) Quinolone derivatives
HK23979A (en) Piperidyl-triazine derivatives
GB1550160A (en) 4-hydroxypyrrolidin-2-one derivatives
GB1520812A (en) Benzhydrylsulphinyl derivatives
IL48209A0 (en) Amidinourea derivatives
ZA761097B (en) Quinolone derivatives
IL49706A (en) Anhydro-vinca derivatives
AU1597876A (en) Ortho-aminobutyrophenone derivatives
JPS51133263A (en) Halogen derivatives
AU1074176A (en) Oxadiazolinone derivatives
IL59758A0 (en) -amino- , -bis-carobxy-alkane derivatives
GB1540845A (en) 6-oxo-pyrimidine derivatives
IE44308L (en) Androsten-17-one derivatives
CY1151A (en) Cis-bicyclooctyl-alkyl-amine derivatives
GB1554720A (en) Pyridthione derivatives
GB1486104A (en) Phthalimidopiperidine derivatives
GB1545577A (en) N-alkyl-3-phenylisoxazole-4-carboxamide derivatives
IL49102A0 (en) Triazolobenzocycloalkylthiadiazine derivatives
AU1661376A (en) Morphanthridine derivatives
GB1520011A (en) Benodioxole derivatives
JPS5253880A (en) Alkaloid derivatives
JPS51127095A (en) Triazolocycloalkylthiaziazine derivatives
JPS51127096A (en) Triazorocycloalkylhydrothazine derivatives
GB1520682A (en) Monochloro-striazine derivatives
GB1531598A (en) Pyrazolo-pyridine derivatives